The story of Sildenafil presents a challenging picture for shareholders. While the initial launch generated massive gains, the expiration of its intellectual property protection opened the avenue to generic alternatives, dramatically diminishing sales. This creates a particular challenge for pharmaceutical companies relying on similar blockbuster m

The legacy of Viagra, and its developer copyright, presents a challenging case study for investors. Originally a blockbuster drug, producing billions in income, its patent expiration created a deluge of knock-off medications, significantly diminishing its here position . While specific pharmaceutical companies may attempt to capitalize on male sexu